Jul. 16 at 11:05 AM
Oppenheimer⬆️
$URGN's PT to
$50 and reiterated at Outperform after speaking w/ MGMT..
$CGON $TYRA MRK LLY IBRX
Here's what Oppenheimer said in its note to investors:
We increase our sales estimates following recent conversations with management.
We now project 2026-28E Zusduri sales of
$210M,
$448M, and
$648M vs.
$204M,
$411M, and
$595M, respectively.
For the three remaining 2026 quarters to be reported, we now project Zus sales of
$43.0M,
$60.0M, and
$78.0M vs. consensus (Visible Alpha) estimates of
$38.5M,
$48.1M, and
$54.5M, respectively.
We expect URGN to report 2Q26 financials in early August.
We see continued outperformance following the recent run (shares up 110% since April 1 vs. +22% XBI) and raise our PT to
$50 (from
$40).
